Actualités Sanofi - SAN | Actions Euronext

Outils de qualité professionnelle, pour des investisseurs individuels.

Press Release: Sanofi in discussions to sell a controlling stake in Opella

Press Release: Sanofi in discussions to sell a controlling stake in Opella Sanofi in discussions to sell a controlling stake in Opella Paris...

Communiqué de presse : Sanofi en discussions pour céder une participation majoritaire dans Opella

Communiqué de presse : Sanofi en discussions pour céder une participation majoritaire dans Opella Sanofi en discussions pour céder une...

Press Release: Sanofi in discussions to sell a controlling stake in Opella

Sanofi in discussions to sell a controlling stake in Opella Paris, October 11, 2024. Sanofi today announces...

Communiqué de presse : De nouvelles données sur le Beyfortus présentées à l’IDWeek confirment son efficacité en situation réelle contre les infections dues au VRS et le risque d’hospitalisation chez les nourrissons

Communiqué de presse : De nouvelles données sur le Beyfortus présentées à l’IDWeek confirment son efficacité en situation réelle contre les...

Press Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants

New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and...

Press Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants

Press Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants New...

Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD

Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic...

Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD

Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent is...

Communiqué de presse : Dupixent est le premier médicament biologique approuvé aux États-Unis pour le traitement de la BPCO

Communiqué de presse : Dupixent est le premier médicament biologique approuvé aux États-Unis pour le traitement de la BPCO Dupixent est le...

Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD

Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent approved in the US as the...

Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on...

Forums

Afficher les forums

Sanofi - Fin de la correction ?	103
Sanofi-Aventis	102
Sanofi qu''est ce que tu attends ?	10
Warrant: SANOFI-AVENTIS	0
Warrants: SANOFI	0
Warrants : SANOFI AVENTIS	0
SANOFI	0
SANOFI-AVENTIS	1
Sanofi-Aventis	38

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Sanofi (SAN)

Outils de qualité professionnelle, pour des investisseurs individuels.

SAN Actualités

Press Release: Sanofi in discussions to sell a controlling stake in Opella

Communiqué de presse : Sanofi en discussions pour céder une participation majoritaire dans Opella

Press Release: Sanofi in discussions to sell a controlling stake in Opella

Communiqué de presse : De nouvelles données sur le Beyfortus présentées à l’IDWeek confirment son efficacité en situation réelle contre les infections dues au VRS et le risque d’hospitalisation chez les nourrissons

Press Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants

Press Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants

Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD

Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD

Communiqué de presse : Dupixent est le premier médicament biologique approuvé aux États-Unis pour le traitement de la BPCO

Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD

Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD

Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD

Communiqué de presse : Dupixent, premier médicament biologique approuvé en Chine pour le traitement de la BPCO

Press Release: Availability of the Q3 2024 Aide mémoire

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Sanofi (SAN) Actualités

Sanofi (SAN)

Outils de qualité professionnelle, pour des investisseurs individuels.

SAN Actualités

Press Release: Sanofi in discussions to sell a controlling stake in Opella

Communiqué de presse : Sanofi en discussions pour céder une participation majoritaire dans Opella

Press Release: Sanofi in discussions to sell a controlling stake in Opella

Communiqué de presse : De nouvelles données sur le Beyfortus présentées à l’IDWeek confirment son efficacité en situation réelle contre les infections dues au VRS et le risque d’hospitalisation chez les nourrissons

Press Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants

Press Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants

Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD

Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD

Communiqué de presse : Dupixent est le premier médicament biologique approuvé aux États-Unis pour le traitement de la BPCO

Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD

Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD

Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD

Communiqué de presse : Dupixent, premier médicament biologique approuvé en Chine pour le traitement de la BPCO

Press Release: Availability of the Q3 2024 Aide mémoire

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application